Fineline Cube

Follow:
14855 Articles
Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets
CompanyDeals

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India
CompanyDeals

Wellington Zhaotai Therapies Signs USD 130 Million CAR‑T Sublicensing Agreement with BioOra – Advancing Cell Therapy Commercialization in International Markets Beyond Greater China and India

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau
CompanyDeals

Mundipharma and ShanZeBIO Strike Strategic Licensing Agreement for REZZAYO/XIUNIS – Bringing Once‑Weekly Rezafungin, the First Second‑Generation Echinocandin, to Mainland China, Hong Kong, and Macau

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories
CompanyDeals

Synmosa Biopharma Inks Exclusive Licensing Deal with Nxera Pharma for Insomnia Therapy Quviviq – Daridorexant Expansion Across Eight Asia‑Pacific Territories

Huadong Medicine's Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults
CompanyDrug

Huadong Medicine’s Oral GLP‑1 Agonist Conveglipron Trometamol (HDM1002) Clears NMPA Marketing Application Acceptance for Long‑Term Weight Control in Adults

Pfizer's Hympavzi Wins NMPA Approval for a New Indication in China – World's First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors
CompanyDrug

Pfizer’s Hympavzi Wins NMPA Approval for a New Indication in China – World’s First Once‑Weekly Non‑Factor Subcutaneous Therapy Extends to Hemophilia A and B with Inhibitors

Hybio Pharmaceutical's Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH
CompanyDrug

Hybio Pharmaceutical’s Oral HY3003 Tablets Clear NMPA Clinical Trial Application Acceptance – A Class 1 GLP‑1R/GIPR/GCGR Triple Agonist for Weight Loss, Type 2 Diabetes, and MASH

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million
Company

BeOne Medicines Reports Q3 2026 Global Revenues of USD 1.9 Billion, Up 34 % – BRUKINSA Tops USD 1.4 Billion as GAAP Net Income Reaches USD 385 Million

GenSci's Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis
CompanyDrug

GenSci’s Inhaled siRNA GenSci117 Targeting MMP7 Clears NMPA Registration Clinical Trial Acceptance – A Class 1 RNAi Candidate for Idiopathic Pulmonary Fibrosis

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones
CompanyDeals

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes
Company

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion
Company

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion